Efficacy and safety of febuxostat in renal transplant recipients with hyperuricemia

Chineae Journal of Organ Transplantation Pub Date : 2019-03-20 DOI:10.3760/CMA.J.ISSN.0254-1785.2019.03.008

Jiajia Jiang, Q. Fu, Sizhe Long, Huanxi Zhang, Xiaojun Su, Jun Li, Chenglin Wu, R. Deng, Longshan Liu, Wujun Zhang, Changxi Wang

{"title":"Efficacy and safety of febuxostat in renal transplant recipients with hyperuricemia","authors":"Jiajia Jiang, Q. Fu, Sizhe Long, Huanxi Zhang, Xiaojun Su, Jun Li, Chenglin Wu, R. Deng, Longshan Liu, Wujun Zhang, Changxi Wang","doi":"10.3760/CMA.J.ISSN.0254-1785.2019.03.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients. \n \n \nMethods \nA total of 124 renal transplant patients with hyperuricemia receiving febuxostat between June 2016 and July 2018 were retrospectively analyzed. Uric acid (UA), liver function and renal function parameters before and 3 months after treatment were compared. Adverse events, recipient and renal allograft survival were recorded throughout the follow-up period. \n \n \nResults \nSerum level of uric acid significantly decreased after 3-month treatment (P<0.001). And 66.1 % of them achieved target UA level at Month 3 after dosing. Estimated glomerular filtration rate (eGFR) was maintained. No severe adverse event was observed. All recipient and renal grafts survived during the follow-up period. \n \n \nConclusions \nFebuxostat is both effective and safe in the treatment of hyperuricemia in renal transplant. \n \n \nKey words: \nRenal transplantation; Hyperuricemia; Efficacy","PeriodicalId":9885,"journal":{"name":"Chineae Journal of Organ Transplantation","volume":"38 1","pages":"158-161"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chineae Journal of Organ Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-1785.2019.03.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients. Methods A total of 124 renal transplant patients with hyperuricemia receiving febuxostat between June 2016 and July 2018 were retrospectively analyzed. Uric acid (UA), liver function and renal function parameters before and 3 months after treatment were compared. Adverse events, recipient and renal allograft survival were recorded throughout the follow-up period. Results Serum level of uric acid significantly decreased after 3-month treatment (P<0.001). And 66.1 % of them achieved target UA level at Month 3 after dosing. Estimated glomerular filtration rate (eGFR) was maintained. No severe adverse event was observed. All recipient and renal grafts survived during the follow-up period. Conclusions Febuxostat is both effective and safe in the treatment of hyperuricemia in renal transplant. Key words: Renal transplantation; Hyperuricemia; Efficacy

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非布司他治疗肾移植受者高尿酸血症的疗效和安全性

目的评价非布司他治疗肾移植术后高尿酸血症的疗效和安全性。方法回顾性分析2016年6月至2018年7月接受非布司他治疗的124例高尿酸血症肾移植患者。比较治疗前和治疗后3个月的尿酸、肝功能、肾功能参数。在整个随访期间记录不良事件、受体和同种异体肾移植存活。结果治疗3个月后血清尿酸水平明显降低(P<0.001)。66.1%的患者在给药后第3个月达到目标UA水平。维持估计的肾小球滤过率(eGFR)。未观察到严重的不良事件。在随访期间，所有受体和肾移植均存活。结论非布司他治疗肾移植术后高尿酸血症安全有效。关键词:肾移植;高尿酸血;功效

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chineae Journal of Organ Transplantation

自引率

0.00%

发文量